ClinicalTrials.gg
CompletedNCT05782283ADVANCEUpdated Oct 16, 2026Results posted

A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram

An interventional study of ACE (AI-Cirrhosis-ECG) 2.0 in Cirrhosis, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 16, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Fibrosis by Mayo Clinic — 4 open to participants now, 4 under way, none of them phase 3. Fibrosis · Mayo Clinic.

Started
2023
the only one that year
No phase
3 of 11
2 open now
Registered
9th of 11
by date

Among the 11 studies in Fibrosis by Mayo Clinic, this one is the only one that started in 2023, is one of 3 with no phase, and was the 9th registered.

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

Browse Fibrosis studies →

Open to participants now

4 of the 11 studies in Fibrosis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Fibrosis by Mayo Clinic, or all of them as a file.
02

Study summary

The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.

Read the detailed description

A pragmatic, cluster randomized trial in 45 Mayo Clinic primary care practices will be conducted over a period of 6 months with 6 months of follow up. Care teams will be randomized 1:1 to intervention or usual care, stratified by region and patient volume. In the intervention arm, the DULCE score will be used to alert consenting providers to the likelihood of advanced liver disease with a recommendation for a FibroTest-ActiTest. The primary endpoint will be detection of advanced liver disease. Secondary outcomes will include completion of noninvasive fibrosis assessment tests and hepatology referral within 180 days of ECG, new diagnosis of liver disease stratified by etiology (nonalcoholic fatty liver disease, alcohol-associated liver disease, hepatitis C, and others) and severity (compensated with and without clinically-significant portal hypertension, and decompensated disease), initiation of prophylactic nonselective beta-blockers and imaging for hepatocellular carcinoma surveillance, according to published society guidelines. Post-study surveys to participating clinicians will be applied.

03

Conditions studied

  • Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Criteria:

Inclusion criteria

Inclusion Criteria:

  • Primary care clinicians (physicians, nurse practitioners, and physician assistants).
  • Part of a team that cares for adult patients (≥18 years).
  • Have the ability to order .
  • Consent will be obtained from primary care clinicians.
  • Patients' data will be collected from electronic medical records (EMR).
  • Adult patients (≥ 18 years) undergoing an ECG for any indication over a period of 6 months will be included.

Exclusion criteria

Exclusion Criteria:

  • Patients with known cirrhosis based on noninvasive fibrosis assessment tests, liver or complications of decompensated disease, or with a documented history of cirrhosis identified by clinical notes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • No intervention
    Group 1: Usual Care Group-Clinicians

    Primary care providers will treat subject per standard of care

  • Experimental
    Group 2: Electrocardiogram AI Group-Clinicians

    The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.

    Device: ACE (AI-Cirrhosis-ECG) 2.0

  • No intervention
    Group 3: Usual Care Group-Patients

    Patients will receive standard of care

  • Experimental
    Group 4: Electrocardiogram AI Group-Patients

    Patients whose Clinician will be alerted by the ACE (AI-Cirrhosis-ECG) 2.0 to the likelihood of advanced liver disease with a recommendation for laboratory tests.

    Device: ACE (AI-Cirrhosis-ECG) 2.0

Interventions

  • DeviceACE (AI-Cirrhosis-ECG) 2.0

    An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.

06

What researchers measure

Primary outcomes

  1. New Diagnosis of Advanced Chronic Liver Disease

    The primary objective of this pragmatic trial is to validate a deep learning-based machine learning (ML) model for early detection of cirrhosis-associated signals on digitized ECG. The primary outcome is the number of participants with new diagnosis of advanced liver disease as assessed by a novel electrocardiogram-enabled convoluted neural network (CNN) compared to standard of care at 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Number of Participants to Not Complete Recommended Testing

    The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice. Number of participants to not complete the recommended testing according to the electrocardiogram-enabled CNN.

    Time frame: 6 months

07

Results

Posted Oct 16, 2026

Participant flow

Primary care clinicians who care for adult patients (≥18 years), including physicians and advanced care practitioners, across 45 primary care practices in both urban and rural communities in Southern Minnesota and Wisconsin were eligible to participate.

Participant flow — Overall Study
MilestoneGroup 1: Usual Care Group-ClinicianGroup 2: Electrocardiogram Machine Learning Group-ClinicanGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-Patients
Started12212675628034
Completed12212375628034
Not completed0300
Withdrew: Withdrawal by subject0300

Outcome measures

PrimaryNew Diagnosis of Advanced Chronic Liver Disease

The primary objective of this pragmatic trial is to validate a deep learning-based machine learning (ML) model for early detection of cirrhosis-associated signals on digitized ECG. The primary outcome is the number of participants with new diagnosis of advanced liver disease as assessed by a novel electrocardiogram-enabled convoluted neural network (CNN) compared to standard of care at 6 months.

Time frame:
6 months
Reported as:
Count of participants · Participants
New Diagnosis of Advanced Chronic Liver Disease
ParticipantsUsual Care GroupElectrocardiogram Machine Learning Group
New Diagnosis of Advanced Chronic Liver Disease3578
SecondaryNumber of Participants to Not Complete Recommended Testing

The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice. Number of participants to not complete the recommended testing according to the electrocardiogram-enabled CNN.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants to Not Complete Recommended Testing
ParticipantsGroup 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-Patients
Number of Participants to Not Complete Recommended Testing——75147764

Adverse events

Collected over Adverse events were not monitored or assessed for any clinician or patient.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Usual Care Group-Clinicians———
Group 2: Electrocardiogram Machine Learning Group-Clinicians———
Group 3: Usual Care Group-Patients———
Group 4: Electrocardiogram Machine Learning Group-Patients———

Baseline characteristics

This is a pragmatic trial in which clinicians caring for adult primary care patients were consented and enrolled. Data analysis was conducted in their patients who underwent ECGs during the study period.

Age, Continuous
Age, Continuous(years)Group 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-PatientsTotal
Mean46.4 ± 10.345.7 ± 9.963.1 ± 18.663.8 ± 18.063.2 ± 18.3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Group 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-PatientsTotal
Female3438442739278426
Male7447313541077363
Prefer not to disclose33006
Unknown or Not Reported11380049
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-PatientsTotal
Hispanic or Latino00225202427
Not Hispanic or Latino007228770514933
Unknown or Not Reported122126109127484
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-PatientsTotal
American Indian or Alaska Native00342357
Asian6488107205
Native Hawaiian or Other Pacific Islander00000
Black or African American01131177309
White100737175758914937
More than one race00000
Unknown or Not Reported1648134138336
Region of Enrollment
Region of Enrollment(participants)Group 1: Usual Care Group-CliniciansGroup 2: Electrocardiogram Machine Learning Group-CliniciansGroup 3: Usual Care Group-PatientsGroup 4: Electrocardiogram Machine Learning Group-PatientsTotal
United States1221267562803415844
08

Study locations

1 site
  • Mayo Clinic Minnesota
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Calleri A, Yazarkan Y, Liu K, Kassmeyer BA, Lennon RJ, Rattan P, Seid A, Bernard ME, Singh G, Deyo-Svendsen ME, King G, Stacey SK, Olofson A, Allen A, Ahn JC, Friedman PA, Kamath PS, Attia ZI, Noseworthy PA, Shah VH, Rushlow D, Simonetto DA. Clinician engagement shapes the impact of AI-based ECG screening for chronic liver disease in primary care. NPJ Digit Med. 2026 May 9;9(1):553. doi: 10.1038/s41746-026-02718-y. PubMed 42106573 ↗
  • Simonetto DA, Rushlow D, Liu K, Calleri A, Kassmeyer BA, Lennon RJ, Rattan P, Bernard ME, Singh G, Deyo-Svendsen ME, King G, Stacey SK, Olofson A, Allen A, Ahn JC, Friedman PA, Kamath PS, Attia ZI, Noseworthy PA, Shah VH. Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial. Nat Med. 2026 Jan;32(1):160-167. doi: 10.1038/s41591-025-04058-y. Epub 2025 Dec 17. PubMed 41408416 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2025, 28 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 186 non-industry interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's 28 months is below that.

Counting every sponsor, half of 195 studies reached it within 32 months; a quarter within 18 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Mar 23, 2023
StartActual
Apr 18, 2023
Primary completionActual
Sep 1, 2025
CompletionActual
Sep 1, 2025
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Enrollment
279→248
Oct 16, 2026
Interventions
Arm changed Usual Care Group→Group 1: Usual Care Group-Clinicians; Electrocardiogram AI Group→Group 2: Electrocardiogram AI Group-Clinicians. Arms added: Group 3: Usual Care Group-Patients·Group 4: Electrocardiogram AI Group-Patients
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore The primary objective of this pragmatic trial is to validate a deep learning-based artificial intelligence (AI) model for early detection of cirrhosis-associated signals on digitized ECG.Now New Diagnosis of Advanced Chronic Liver DiseaseTime frame: 6 months
Oct 16, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice.Now Number of Participants to Not Complete Recommended TestingTime frame: 6 months
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    Enrollment 279→248
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore The primary objective of this pragmatic trial is to validate a deep learning-based artificial intelligence (AI) model for early detection of cirrhosis-associated signals on digitized ECG.Now New Diagnosis of Advanced Chronic Liver DiseaseTime frame: 6 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice.Now Number of Participants to Not Complete Recommended TestingTime frame: 6 months
    Interventions Arm changed Usual Care Group→Group 1: Usual Care Group-Clinicians; Electrocardiogram AI Group→Group 2: Electrocardiogram AI Group-Clinicians. Arms added: Group 3: Usual Care Group-Patients·Group 4: Electrocardiogram AI Group-Patients
    + 3 other changes: index terms, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05782283
Lead sponsor
Mayo Clinic
Responsible party
Douglas (Doug) A. Simonetto (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 23, 2023
Start date
Apr 18, 2023
Primary completion
Sep 1, 2025
Completion
Sep 1, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Douglas Simonetto, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion